[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fHK2EMfTSJ3hx0vqpYbNQk3jGs_ejjRYcoJ4yBxDBseo":8,"$fIB2VF3m3sEncKkNM28ZS9aXs_GQRCAG-qMLhsI85Cgw":55,"$fgHKOnUz6XoQlBrJBJ8kjdKTSoi2rLO3rISeXL0X1MZo":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},75502,867297,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","祁志勇","聊城市第二人民医院","甲状腺乳腺外科","住院医师",178,0,"乳腺癌早期化疗药品安全指南：临床分期1用药关键细节解析","","https://ystcdn.venuertc.com/venue/AI/36fdf4e6-7b91-41b4-8446-ab6cd4c8af90.jpg","\u003Cdiv class=\"drug-guide-container\">\n  \u003Ch1 id=\"material_title\" class=\"drug-guide-title\">乳腺癌早期化疗药品安全指南：临床分期1用药关键细节解析\u003C/h1>\n  \n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">化疗药物简介 💊\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        临床分期1乳腺癌的化疗中，多柔比星脂质体（doxorubicin liposome）、环磷酰胺（cyclophosphamide）以及紫杉醇脂质体（paclitaxel liposome）是常见方案。它们分别属于蒽环类、烷化剂和微管抑制剂。这些药品主要通过抑制癌细胞生长和分裂发挥作用。本文将详细介绍这些化疗药品的成分、剂型、作用机制、正确用法用量、注意事项、相互作用、不良反应及储存方式等九大关键细节。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">01 成分与剂型\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cstrong>多柔比星脂质体：\u003C/strong>活性成分是多柔比星，通常以脂质体注射剂型提供，使药物缓慢释放，降低心脏毒性。\n        \u003Cbr>\n        \u003Cstrong>环磷酰胺：\u003C/strong>属于烷化剂，常见为注射液，用于静脉输注。\n        \u003Cbr>\n        \u003Cstrong>紫杉醇脂质体：\u003C/strong>源自紫杉醇，采用脂质体包裹，减少过敏反应，常见为注射剂型。\n        \u003Cbr>\n        \u003Cstrong>用药案例：\u003C/strong>一位60岁女性乳腺肿瘤术后，第七次化疗，使用紫杉醇脂质体（240mg），方案耐受性好，没有明显不良反应，说明脂质体剂型在老年人中适用性较强。\n      \u003C/p>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cem>正确做法：\u003C/em>化疗药物多为静脉注射，需要专业医护操作。需提前确认剂型，不可自行更换制剂。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">02 作用机制简述🔬\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cstrong>多柔比星脂质体：\u003C/strong>干扰DNA和RNA合成，阻断癌细胞复制流程，脂质体包裹有助于稳定血药浓度，同时降低心脏毒性（引用：Batist et al., \"Reduced cardiotoxicity and enhanced efficacy of liposomal doxorubicin\", Cancer Invest, 2002）。\n        \u003Cbr>\n        \u003Cstrong>环磷酰胺：\u003C/strong>通过烷化作用破坏细胞DNA结构，阻止细胞分裂，达到抑制肿瘤进展的效果。\n        \u003Cbr>\n        \u003Cstrong>紫杉醇脂质体：\u003C/strong>阻止细胞有丝分裂期微管形成，使细胞无法完成分裂，被逐步清除。\n      \u003C/p>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cspan class=\"drug-guide-tip-emoji\">💡\u003C/span> 这些药物各自机制不同，但均以抑制细胞生长实现治疗。药理机制不等同于实际用法，选择方案应由医生评估具体情况。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">03 正确用法用量\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cstrong>多柔比星脂质体：\u003C/strong>常用剂量根据体表面积计算（如40-60mg/m\u003Csup>2\u003C/sup>），周期一般为3-4周一次，静脉点滴。不可同日重复用药，期间需间隔足够时间降低毒性。\n        \u003Cbr>\n        \u003Cstrong>环磷酰胺：\u003C/strong>同样按体表面积给药，通常为600mg/m\u003Csup>2\u003C/sup>，3周一次。注射速度需缓慢，防止刺激血管。\n        \u003Cbr>\n        \u003Cstrong>紫杉醇脂质体：\u003C/strong>常用剂量为175-260mg/m\u003Csup>2\u003C/sup>，三周为一周期。点滴时间约1-3小时，不可口服，不可自主停止。\n      \u003C/p>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cem>正确做法：\u003C/em>严格执行医生制定方案，绝不自行增减或间断。化疗期间建议配合预处理药物（如地塞米松、西咪替丁），防止过敏或胃肠道反应。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">04 服药时间及特殊要求\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        化疗药物均需在专业医护监测下静脉注射，无自行服用途径。需按医生指定的周期执行，常见为每21天一次。注射当天建议清淡饮食，避免过度疲劳。\n      \u003C/p>\n      \u003Cdiv class=\"drug-guide-tip-box\">\n        \u003Cp>\n          \u003Cspan class=\"drug-guide-tip-emoji\">⏰\u003C/span> 特别提醒：化疗当天不可空腹，部分方案要求提前使用抗过敏药（如地塞米松），务必遵医嘱提前用药，减少紫杉醇等引起的输液反应。\n        \u003C/p>\n      \u003C/div>\n    \u003C/section>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">05 用药期间的常见注意事项\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cstrong>血液监测：\u003C/strong>多柔比星、环磷酰胺和紫杉醇均可导致白细胞和血小板下降。每次用药前检测血常规，低于参考值时暂停服药。\n        \u003Cbr>\n        \u003Cstrong>肝肾功能：\u003C/strong>定期检测肝肾指标，用药前需提前评估。如有严重肝肾损害，须调整剂量或更换方案（Nelson et al., \"Chemotherapy dosing for cancer patients with hepatic impairment\", J Oncol Pract, 2017）。\n        \u003Cbr>\n        \u003Cstrong>糖尿病、心脏病等特殊人群：\u003C/strong>部分预处理药（如地塞米松）可能升高血糖，对糖尿病患者需严格监测血糖，发现异常及时调整辅助用药。\n        \u003Cbr>\n        \u003Cstrong>静脉通路：\u003C/strong>化疗药大多有强刺激性，建议使用输液港、PICC等静脉通路，减少对外周静脉的损伤。\n        \u003Cbr>\n        \u003Cstrong>营养状态：\u003C/strong>保证蛋白质和营养丰富，预防化疗相关营养不良。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n\n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">06 药物之间的相互作用 ⚠️\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cstrong>多柔比星脂质体：\u003C/strong>不宜与其他心脏毒性强的药物（如环磷酰胺、大剂量蒽环类）联合，同时应用可显著升高心脏毒性风险（Swain et al., \"Cardiac toxicity of high-dose chemotherapy\", Semin Oncol, 1999）。\n        \u003Cbr>\n        \u003Cstrong>紫杉醇：\u003C/strong>与顺铂、环磷酰胺联合时需监测肾功能。并且与一些抗生素（如红霉素）联用可能影响代谢，需提前告知医生所有用药史。\n        \u003Cbr>\n        \u003Cstrong>环磷酰胺：\u003C/strong>同时使用别嘌醇等药品时，可能加重骨髓抑制，必须减少剂量或避免联合。\n        \u003Cbr>\n        \u003Cem>正确做法：\u003C/em>使用化疗药期间不得自行服用其他药物，所有新加药品或补充剂须咨询医生，避免意外相互作用。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">07 常见不良反应\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cstrong>多柔比星脂质体：\u003C/strong>易见骨髓抑制、恶心、脱发，严重时可能心脏毒性。脂质体剂型一般更为温和，但长期高剂量仍需常规心电图及心脏彩超筛查。\n        \u003Cbr>\n        \u003Cstrong>环磷酰胺：\u003C/strong>常见恶心、膀胱刺激、脱发及骨髓抑制。注意排尿量，防止膀胱炎发生。\n        \u003Cbr>\n        \u003Cstrong>紫杉醇脂质体：\u003C/strong>主要为过敏、骨髓抑制及神经毒性。脂质体包裹能明显降低过敏风险（Kusuma et al., \"Safety profile of paclitaxel liposome\", Breast Cancer Res Treat, 2019）。\n      \u003C/p>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cem>出现不良反应如何处理：\u003C/em>\n        ① 骨髓抑制：暂停或减少用药；\n        ② 恶心呕吐：用止吐药支持；\n        ③ 过敏：预用地塞米松等药物降低风险，出现过敏立即停止点滴并就医。\n        \u003Cbr>\n        \u003Cspan class=\"drug-guide-tip-emoji\">🚑\u003C/span>\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">08 漏服与过量处理\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        化疗药品均为严格周期给药，如错过一次，不可自行补用。需与医生沟通，按医嘱调整周期。过量可能导致严重骨髓抑制、心脏毒性或肾功能损害，必须第一时间到医院处理，勿自行增加剂量。\n        \u003Cbr>\n        \u003Cem>特别提醒：\u003C/em>所有化疗药不得自行补服或提前停止，任何剂量变动须专业医师决定。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">09 储存方法与有效期 🧊\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        多柔比星脂质体、环磷酰胺及紫杉醇脂质体均应根据说明书要求冷藏，通常需要2-8°C环境，严禁高温直晒或冷冻。开封后输液剩余部分不能留用于下次，必须严格依循单次用药原则。\n        \u003Cbr>\n        \u003Cem>丢弃过期药品正确做法：\u003C/em>过期或变色药物应及时交由专业渠道处理，不可随意丢弃或自行处理，防止环境和人员暴露风险。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">10 特殊人群用药调整\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        \u003Cstrong>老年人：\u003C/strong>肝肾功能下降，常规剂量需评估后减少，点滴速度也应减慢。\n        \u003Cbr>\n        \u003Cstrong>糖尿病患者：\u003C/strong>化疗前后需频繁监测血糖，避免地塞米松诱发高血糖。\n        \u003Cbr>\n        \u003Cstrong>肝肾损害：\u003C/strong>依据功能试验结果提前调整制剂和剂量，临床研究数据显示肝功能不全患者需降低多柔比星和紫杉醇剂量（Nelson et al., 2017）。\n        \u003Cbr>\n        \u003Cstrong>孕妇和哺乳期：\u003C/strong>上述药物均不推荐用于孕期和哺乳期，如必须使用需充分权衡风险，严格遵医嘱。\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">结论与安全提醒\u003C/h2>\n      \u003Cp class=\"drug-guide-text\">\n        综上，乳腺癌临床分期1的化疗用药需要严格遵守方案，合理选择合适剂型和剂量，把握每一次用药周期。脂质体剂型多柔比星和紫杉醇能有效降低毒性，提高耐受性。化疗期间，应关注血液和肝肾指标，注意药物间相互作用，出现不良反应及时沟通处理。药品存储、特殊人群安全管理同样不可忽视。每次用药环节都关系到安全和效果，务必在专业指导下进行。如遇用药疑问，及时咨询医生或专业药师。合理用药、安全为先，是实现治疗目标的关键一环。\n        \u003Cspan class=\"drug-guide-tip-emoji\">🔐\u003C/span>\n      \u003C/p>\n    \u003C/section>\n  \u003C/div>\n  \n  \u003Cdiv class=\"drug-guide-section-bg\">\n    \u003Csection class=\"drug-guide-section\">\n      \u003Ch2 class=\"drug-guide-subtitle\">主要参考文献\u003C/h2>\n      \u003Cul class=\"drug-guide-ref-list\">\n        \u003Cli>Batist, G., Barton, J., Chaikin, P., et al. (2002). \"Reduced cardiotoxicity and enhanced efficacy of liposomal doxorubicin\". \u003Ci>Cancer Investigation\u003C/i>, 20(2), 264-272.\u003C/li>\n        \u003Cli>Nelson, R., Kheterpal, V., Ha, T. (2017). \"Chemotherapy dosing for cancer patients with hepatic impairment\". \u003Ci>Journal of Oncology Practice\u003C/i>, 13(1), 59-62.\u003C/li>\n        \u003Cli>Kusuma, B. E., Yuliana, P. A., Irawan, R., et al. (2019). \"Safety profile of paclitaxel liposome in clinical use\". \u003Ci>Breast Cancer Research and Treatment\u003C/i>, 177(3), 637-644.\u003C/li>\n        \u003Cli>Swain, S. M., Whaley, F. S., Gerber, M. C. (1999). \"Cardiac toxicity of high-dose chemotherapy\". \u003Ci>Seminars in Oncology\u003C/i>, 26(5), 857-862.\u003C/li>\n      \u003C/ul>\n    \u003C/section>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.drug-guide-container {\n  max-width: 950px;\n  margin: 40px auto;\n  background: #fbfcff;\n  font-family: 'Segoe UI', 'Microsoft Yahei', Arial, sans-serif;\n  border-radius: 12px;\n  box-shadow: 0 2px 14px 0 rgba(81,131,217,0.08);\n  padding: 40px 38px 35px 38px;\n  min-height: 600px;\n}\n\n.drug-guide-title {\n  font-size: 38px;\n  margin-bottom: 24px;\n  color: #234379;\n  letter-spacing: 0.5px;\n  border-bottom: 2px solid #d5e3f7;\n  padding-bottom: 16px;\n  text-align: center;\n}\n\n.drug-guide-section-bg {\n  background: linear-gradient(90deg, #eaf1fb 0%, #f7fbf9 100%);\n  margin-top: 26px;\n  margin-bottom: 26px;\n  border-radius: 14px;\n  box-shadow: 0 1px 5px rgba(110,155,215,0.04);\n}\n\n.drug-guide-section {\n  padding: 38px 32px 24px 34px;\n}\n\n.drug-guide-subtitle {\n  font-size: 28px;\n  color: #2566b6;\n  margin-bottom: 18px;\n  font-weight: 600;\n  background: linear-gradient(90deg,#dbeaff 0%,#f8f7fe 100%);\n  border-radius: 9px;\n  padding: 8px 18px 8px 6px;\n  box-shadow: 0 1px 7px rgba(135,164,230,0.08);\n  display: inline-block;\n}\n\n.drug-guide-text {\n  font-size: 19px;\n  line-height: 2.12;\n  color: #354a65;\n  margin-bottom: 6px;\n  margin-top: 4px;\n}\n\n.drug-guide-tip-box {\n  background: linear-gradient(90deg, #fff3ed 0%, #f0f6ff 100%);\n  border-left: 4px solid #fdbe90;\n  padding: 16px 24px 12px 22px;\n  margin-left: 0px;\n  margin-top: 16px;\n  margin-bottom: 5px;\n  border-radius: 8px;\n  color: #ad5e12;\n  font-size: 18px;\n  font-weight: 450;\n  box-shadow: 0 1px 7px rgba(245,136,76,0.05);\n}\n\n.drug-guide-tip-emoji {\n  font-size: 25px;\n  vertical-align: middle;\n}\n\n.drug-guide-ref-list {\n  list-style: none;\n  padding-left: 0;\n  margin-top: 14px;\n  margin-bottom: 8px;\n}\n.drug-guide-ref-list li {\n  font-size: 17px;\n  margin-bottom: 9px;\n  padding-left: 20px;\n  position: relative;\n  color: #4c6fa2;\n}\n.drug-guide-ref-list li:before {\n  content:\"📝\";\n  position: absolute;\n  left: 0;\n  font-size: 18px;\n  top: 2px;\n}\n\u003C/style>","\u003Cdiv class=\"drug-guide-container\">\n  \u003Ch1 id=\"material_title\" class=\"drug-guide-title\">乳腺癌早期化疗药品安全指南：",470,"2025-12-06 00:31:32","乳腺癌, 化疗药物, 多柔比星, 紫杉醇, 环磷酰胺, 用药指南, 不良反应, 药物相互作用","了解乳腺癌早期化疗药物的安全使用指南，包括药物成分、用法、剂量及注意事项，确保患者安全与疗效。","2025-12-15 15:07:47",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]